Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes

作者：Sanchez Anthony M J^*; Borrani Fabio; Le Fur Marie Amelie; Le Mieux Anais; Lecoultre Virgile; Py Guillaume; Gernigon Christophe; Collomp Katia; Candau Robin

来源：European Journal of Applied Physiology, 2013, 113(2): 411-418.

DOI：10.1007/s00421-012-2447-0

• beta(2)-Agonist
• Doping
• Force-velocity relationship
• Endurance performance
• Anaerobic performance
• Healthy athletes

This study aimed to investigate the effects on a possible improvement in aerobic and anaerobic performance of oral terbutaline (TER) at a supra-therapeutic dose in 7 healthy competitive male athletes. On day 1, ventilatory threshold, maximum oxygen uptake and corresponding power output were measured and used to determine the exercise load on days 2 and 3. On days 2 and 3, 8 mg of TER or placebo were orally administered in a double-blind process to athletes who rested for 3 h, and then performed a battery of tests including a force-velocity exercise test, running sprint and a maximal endurance cycling test at Delta 50 % (50 % between VT and ). Lactatemia, anaerobic parameters and endurance performance ( and time until exhaustion) were raised during the corresponding tests. We found that TER administration did not improve any of the parameters of aerobic performance (p %26gt; 0.05). In addition, no change in kinetic parameters was found with TER compared to placebo (p %26gt; 0.05). Moreover, no enhancement of the force-velocity relationship was observed during sprint exercises after TER intake (p %26gt; 0.05) and, on the contrary, maximal strength decreased significantly after TER intake (p %26lt; 0.05) but maximal power remained unchanged (p %26gt; 0.05). In conclusion, oral acute administration of TER at a supra-therapeutic dose seems to be without any relevant ergogenic effect on anaerobic and aerobic performances in healthy athletes. However, all participants experienced adverse side effects such as tremors.

• 出版日期2013-2